ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer - EurekAlert

ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer  EurekAlert

Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which is best? The answer seems easy: Just compare the drugs' clinical ...



Comments

Popular posts from this blog

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Oncology: The disease, dynamics & challenges of market research

Division of Continuing Professional Development